Caxton Associates LP Ligand Pharmaceuticals Inc Transaction History

Caxton Associates LP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$49.57 - $72.63 $904,652 - $1.33 Million	18,250 New	18,250 $1.3 Million
Q3 2020 Nov 16, 2020	SELL	$89.56 - $126.72 $568,437 - $804,291	-6,347 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$68.28 - $123.65 $209,756 - $379,852	3,072 Added 93.8%	6,347 $710,000
Q1 2020 May 15, 2020	BUY	$63.37 - $107.88 $207,536 - $353,307	3,275 New	3,275 $238,000
Q4 2018 Feb 14, 2019	SELL	$128.36 - $272.13 $397,402 - $842,514	-3,096 Closed	0 $0
Q3 2018 Nov 14, 2018	SELL	$211.18 - $274.49 $157,540 - $204,769	-746 Reduced 19.42%	3,096 $850,000
Q2 2018 Aug 14, 2018	SELL	$150.77 - $207.98 $24,877 - $34,316	-165 Reduced 4.12%	3,842 $796,000
Q1 2018 May 15, 2018	BUY	$138.63 - $182.62 $555,490 - $731,758	4,007 New	4,007 $662,000

257

18.2M

26.8K

9.3K

Ticker LGND
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 16,882,800
Market Cap $2.02B
Description
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19;...

Get notified when there are updates to the investment portfolio of Caxton Associates LP, based on Form 13F filings with the SEC.

Stay updated on Caxton Associates LP with notifications on news.